Title : A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

Pub. Date : 2011 Aug 1

PMID : 21246525






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF-kappaB, may have antitumor activity in adenoid cystic carcinoma (ACC). Bortezomib nuclear factor kappa B subunit 1 Homo sapiens